ImmunoCellular Therapeutics (OTCBB: IMUC) has entered into an agreement with University of Pittsburgh under where Pitt has licensed intellectual property to the company surrounding EphA2, a tyrosine kinase receptor that is highly expressed by ovarian cancer and other advanced and metastatic malignancies.
This agreement grants a world-wide exclusive license to the Pitt intellectual property for ovarian and pancreatic cancers, and a world-wide non-exclusive license to the Pitt intellectual property for brain cancer.
Financial terms of the agreement were not disclosed. The company will employ the Pitt intellectual property in the development and commercialization of ICT-140, a multivalent, dendritic cell-based vaccine for the treatment of ovarian cancer.
Please see our other post(s) on IMUC, PrimaBioMed and Merck KG (StimuVax).